Select Page
Investors

Investors

Successful IPO of MEDESIS PHARMA, a biotechnology pharmaceutical company, on Euronext Growth Paris® (ISIN: FR0010844464, MNEMO: ALMDP). Visit the Investors section for more information
Viral diseases

Viral diseases

Medesis Pharma is developing a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 – NanoManganese®). Preclinical trials have been carried out with the French Armed Forces Biomedical Research Institute (IRBA). (Study...